Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy

Toto, Lisa; Ruggeri, Maria Ludovica; Evangelista, Federica; Viggiano, Pasquale; D’Aloisio, Rossella; Nicola, Chiara De; Falconio, Gennaro; Nicola, Marta Di; Porreca, Annamaria; Mastropasqua, Rodolfo

doi:10.1038/s41433-022-02091-6

Cited by 7 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exclusion criteria were also refractive error >±3, macular pathologies other than CSC, as well as the presence of MNV and any ocular surgery. Patients with a history of any treatment in the previous 3 months and of any previous treatment that could affect CVI were also excluded [24,25]. A history of any previous medications that could cause subretinal fluid was also recorded.…”

Section: Methodsmentioning

confidence: 99%

En Face Choroidal Vascularity in Both Eyes of Patients with Unilateral Central Serous Chorioretinopathy

Tatti

Iovino

Demarinis

et al. 2022

JCM

View full text Add to dashboard Cite

The aim of this study was to evaluate the choroidal vascularity analyzing en face optical coherence tomography (OCT) images in patients with unilateral central serous chorioretinopathy (CSC). We retrospectively evaluated 40 eyes of 20 CSC patients and 20 eyes of 10 gender- and age-matched healthy individuals. The sample consisted of: (1) CSC affected eyes; (2) unaffected fellow eyes; (3) healthy eyes. Multiple cross-sectional enhanced depth imaging OCT scans were obtained to create a volume scan. En face scans of the whole choroid were obtained at 5μm intervals and were binarized to calculate the choroidal vascularity index (CVI). The latter, defined as the proportion of the luminal area to the total choroidal area, was calculated at the level of choriocapillaris, superficial, medium and deep layers. No significant differences between choriocapillaris, superficial, medium and deep CVI were found in both eyes of CSC patients, whereas a significant different trend of changes was found in healthy eyes. Nevertheless, the en face CVI shows no difference between affected fellow and healthy eyes. In conclusion, CSC-affected eyes and fellow eyes showed a similar vascular architecture, with no statistical difference between all choroidal layers.

show abstract

Section: Methodsmentioning

confidence: 99%

En Face Choroidal Vascularity in Both Eyes of Patients with Unilateral Central Serous Chorioretinopathy

Tatti

Iovino

Demarinis

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…3,4 CSC pattern includes two different entities, acute CSC (aCSC) and chronic CSC (cCSC). 5 aCSC has a self-limiting presentation and generally spontaneously resolves within 2 to 3 months. Nevertheless, persistent SRF accumulation leads to gradual deterioration of vision.…”

Section: Introductionmentioning

confidence: 99%

“…cCSC is frequently bilateral (almost 20%) and usually results in a neurosensory and chorioretinal permanent damage. 5 Although the pathogenesis of CSC is poorly understood, the majority of authors hypnotize that choroidal abnormalities are the primary underlying mechanism of this disease. 6 The typical anatomical pattern of CSC is characterized by dilated choroidal vessels in the Haller's layer, with a concomitant thinning of Sattler's layer and choriocapillaris.…”

Section: Introductionmentioning

confidence: 99%

“…While multiple studies have focused on choroidal morphology changes of unilateral CSC following different therapies, 15,16 a recent paper by Toto et al 5 has showed choroidal morphology recovery in both eyes of patients undergoing oral EPL for cCSC with monolateral SRF. However, the current literature lacks evidence regarding long-term choroidal modi cations of the fellow eye in unilateral exudative cCSC in response to oral EPL therapy.…”

Section: Introductionmentioning

confidence: 99%

“…2 Several authors correlated this abnormality to overstimulation of choroidal mineralocorticoids receptor (MR). 5 Thus, an antagonist of MR such as Eplerenone (EPL), has been widely proposed in the treatment of CSC. 9 Although its effectiveness in clinical practice is still controversial, 6,10 several researchers have reported a resolution of SRF and a reduction in subfoveal choroidal thickness (SFCT).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Continuous Eplerenone treatment in chronic central serous chorioretinopathy: long-term results from a pilot study

Boscia

Viggiano

Grassi

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

To assess the long-term morpho-functional retinal and choroidal changes in chronic central serous chorioretinopathy (cCSC) pachychoroid eyes in response to continuous oral eplerenone (EPL) treatment. This pilot study was conducted on patients with unilateral exudative cCSC. We enrolled a total of 34 eyes, 17 with exudative cCSC and 17 non-affected fellow eyes of 17 patients. Baseline best-corrected visual acuity (BCVA) and anatomical (structural optical coherence tomography [OCT] and OCT angiography) parameters in both eyes were collected at baseline. Follow-up data were collected at 6,12, and 48 months after initiation of EPL treatment. (i) exudative cCSC eyes: Compared with baseline (0.34±0.13 LogMAR), BCVA significantly improved at follow-up examinations (6 months: 0.28±0.13 LogMAR, p=0.039; 12 months: 0.22±0.11 LogMAR, p=0.025; 48 months: 0.21±0.08 LogMAR, p=0.028). Furthermore, there was a significant reduction from baseline in all structural OCT parameters (subretinal fluid and subfoveal choroidal thickness [SFCT]; p<0.05). (ii) non-affected fellow eyes: There was no significant change in BCVA. There was a significant reduction from baseline in SFCT and choriocapillaris flow deficit percentage (p<0.05). In this pilot study, continuous oral EPL therapy in cCSC pachychoroid eyes resulted in long-term morpho-functional improvement. The beneficial effect of EPL occurred within the first year and was maintained after four years. Based on these preliminary observations, EPL may be effective in the exudative forms of CSC.

show abstract

Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long-Term Effects on the Fellow Eye

Viggiano,

Boscia,

Borrelli

et al. 2023

Ophthalmol Ther

View full text Add to dashboard Cite

Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy

Cited by 7 publications

References 38 publications

En Face Choroidal Vascularity in Both Eyes of Patients with Unilateral Central Serous Chorioretinopathy

En Face Choroidal Vascularity in Both Eyes of Patients with Unilateral Central Serous Chorioretinopathy

Continuous Eplerenone treatment in chronic central serous chorioretinopathy: long-term results from a pilot study

Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long-Term Effects on the Fellow Eye

Contact Info

Product

Resources

About